Kann ich es bekommen?
Ja, wenn ein Arzt entscheidet, dass es für Sie geeignet ist. Liraglutide ist in der EU zugelassen und kann nach einer ärztlichen Prüfung verschrieben werden.
LiraglutideRezeptpflichtig
Ärztliche Online-Beratung für Liraglutide.
Ein in der EU zugelassener Arzt prüft Ihren Fall und stellt, falls Sie geeignet sind, ein elektronisches Rezept aus, das in jeder EU-Apotheke gemäß der Richtlinie 2011/24/EU gültig ist.
- Daily pen with flexible titration
- One of the longest-standing GLP-1s in Europe
- An option when a weekly GLP-1 isn't the right fit
Beratung startenBeratung starten · 25 €/Monat
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird · Das Medikament wird, falls verschrieben, separat in einer Apotheke abgegeben und bezahlt.
IN EINFACHEN WORTEN
Was Liraglutide ist und wie Sie eine Behandlung erhalten
Liraglutid wird einmal täglich unter die Haut gespritzt. Wie Semaglutid ahmt es das natürliche Darmhormon GLP-1 nach. Dieses meldet dem Gehirn, dass Sie genug gegessen haben, wodurch Hunger und Heißhunger abnehmen. Zur Gewichtskontrolle wird es in der EU als Saxenda verkauft und zusammen mit einer kalorienreduzierten Ernährung und mehr körperlicher Aktivität angewendet. Es ist in der EU seit März 2015 zur Gewichtskontrolle zugelassen.
Liraglutide ist seit 23. März 2015 für die Anwendung in der EU zugelassen. Ein zugelassener Arzt kann es Ihnen daher verschreiben, wenn es medizinisch für Sie geeignet ist.
Mehr über Peptide erfahren Sie auf Peptidepedia.
Was kann ich stattdessen nehmen?
Unsere Ärzte prüfen alle Optionen für Gewichtsmanagement und empfehlen, was zu Ihrer Krankengeschichte und Ihren Zielen passt.
Alle Optionen für Gewichtsmanagement ansehenWas zeigen die Studien?
Alle Studien zu Liraglutide sind unten aufgeführt: mit ihrer Registernummer, der Anzahl der Teilnehmenden und der Angabe, ob die Ergebnisse von Fachleuten geprüft wurden oder nur aus einer Mitteilung des Unternehmens stammen.
Zu den StudienGEPRÜFTE EVIDENZ
Liraglutide: Evidenz- und Zulassungsleitfaden.
WAS ES IST
Wie es wirkt
It copies the gut hormone GLP-1, which increases the feeling of fullness and reduces hunger and food cravings.
- GLP-1
ENTWICKLUNGSSTAND
EU-zugelassenes Arzneimittel
Studienregister1 registrierte Studien
Jede NCT-Kennung führt zum Eintrag bei ClinicalTrials.gov. Eine Ergebnismeldung ist nicht dasselbe wie eine begutachtete Veröffentlichung.
| STUDIE / NCT | POPULATION | TEILNEHMENDE | STATUS | ERGEBNIS / ABSCHLUSS |
|---|---|---|---|---|
| SCALE Obesity and Prediabetes (NN8022-1839)NCT01272219 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with treated high blood pressure or abnormal blood fats, without type 2 diabetes; all received lifestyle counselling | 3,731 | Ausgewertet | 2015-07-02 |
Was die Studien berichteten
Die Ergebnisse sind nach Quelle und Evidenzgrad getrennt, damit Fachpublikationen nicht mit Herstellerangaben verwechselt werden.
Fachbegutachtet
Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 (PMID 26132939)| DOSIS ODER GRUPPE | MITTLERE GEWICHTSÄNDERUNG | WOCHEN |
|---|---|---|
| 3.0 mg once daily | −8.0% | 56 |
| Placebo | −2.6% | 56 |
Everyone in the trial also received lifestyle counselling, people with type 2 diabetes were excluded, and the primary result covers 56 weeks only.
BENANNTE SICHERHEITSSIGNALE
Was bei Liraglutide berichtet wurde.
Nausea
Reported by 40.2% of people on liraglutide 3.0 mg versus 14.7% on placebo in the SCALE Obesity and Prediabetes trial.
Diarrhoea
Reported by 20.9% on liraglutide 3.0 mg versus 9.3% on placebo in the same trial.
Constipation
Reported by 20.0% on liraglutide 3.0 mg versus 8.7% on placebo in the same trial.
Vomiting
Reported by 16.3% on liraglutide 3.0 mg versus 4.1% on placebo in the same trial.
Gallstone problems
Acute gallstone events were reported by 2.3% on liraglutide 3.0 mg versus 0.9% on placebo across the EMA weight-management trial pool, mainly gallstones (1.5% versus 0.5%).
Acute pancreatitis
Independently confirmed in 7 people (0.2%) on liraglutide 3.0 mg versus 1 person (under 0.1%) on placebo across the EMA weight-management trial pool.
Serious side effects overall
Serious adverse events were reported in 6.2% of the liraglutide group versus 5.0% of the placebo group in the SCALE Obesity and Prediabetes trial.
25 €/Monat (Abrechnung: 25 € alle 28 Tage)Ärztliche Beratung starten
DarreichungsformFertigpen
HäufigkeitEinmal täglich
ErgebnisseGradual, week by week
Was Sie an Hi-Doctor zahlen25 €/Monat (Abrechnung: 25 € alle 28 Tage)
IN 60 SEKUNDEN
Liraglutide auf einen Blick
- A GLP-1 receptor agonist given as an injection under the skin once a day.
- Adults with a BMI of 30 or more, or 27 or more plus a weight-related illness.
- One injection every day, at any time, built up from 0.6 mg to 3.0 mg.
- Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
Überblick
Was ist Liraglutide?
Wird auch als Saxenda, Victoza vertrieben.
Wirkstoff: Liraglutide · Dosierungen: 0.6 – 3 mg / day
Liraglutide is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity, or overweight with comorbidities.
Compared with weekly GLP-1s, its daily dosing can be useful when flexibility of adjustment matters or when a semaglutide hasn't been tolerated. The doctor weighs this up in your consultation — two GLP-1 agonists are never combined.
SO WIRKT ES
Was Liraglutide in Ihrem Körper bewirkt
Like other GLP-1 analogues, liraglutide mimics a natural gut hormone: it eases hunger signals and produces earlier fullness, so you tend to eat less. Being shorter-acting, its dose is adjusted day by day.
Copies one gut hormone
Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.
Raises fullness, lowers hunger
GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.
Short-acting, so taken daily
Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.
Wie es hilft
Three ways it supports weight loss.
Eases appetite
Earlier fullness and calmer hunger signals through the day.
Flexible dosing
Daily titration lets the doctor fine-tune the dose to your tolerance.
Long EU history
Among the first weight-management GLP-1s approved in Europe.
Was Sie erwartet
A gradual, week-by-week build-up.
Treatment starts at a low daily dose and steps up through the intermediate doses as tolerated. Your doctor sets the pace and adjusts if side effects appear.
- Week 1 · 0.6 mg daily starting dose
- Following weeks · Step up through 1.2, 1.8 and 2.4 mg as tolerated
- Maintenance · 3 mg daily when appropriate
- Ongoing · Follow-up through your account chat
Typical escalation
- Starting dose0.6 mg / day
- Step-ups1.2 → 1.8 → 2.4 mg / day
- Maintenance3 mg / day
Ihr Behandlungsplan ist individuell
Diese Schritte sind nur Richtwerte. Ihr Arzt passt den Plan daran an, wie Sie ansprechen und das Medikament vertragen — und Sie können ihm jederzeit schreiben.
IM ALLTAG
Liraglutide im Alltag anwenden
Inject once every day
Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.
Start low and build up
Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.
Tummy, thigh or upper arm
The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.
Check the pen before use
Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.
Missed dose: the 12 hour rule
If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.
Store pens in the fridge
Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.
Drink enough fluid
Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.
Keep the diet and activity going
Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.
Sicherheit zuerst
Sicherheit, vollständig.
Liraglutide ist ein wirksames Medikament — und wie jedes Medikament birgt es Risiken. Ihr Arzt prüft all dies vor der Verschreibung. Hier ist das ehrliche Bild, nicht nur Beruhigung.
Nebenwirkungen, nach Häufigkeit
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis
- Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder
- Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction
- Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure
- Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes
- A racing or pounding heartbeat while you are resting, which the prescriber needs to review
- Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea), most often while the dose is being increased
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Headache
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes
- Trouble sleeping, mainly during the first three months
- Dizziness
- A change in the sense of taste
- Dry mouth
- Indigestion, gastritis or acid reflux
- Pain in the upper part of the tummy
- Wind, burping or a bloated tummy
- Gallstones
- Rash
- Injection site reactions
- Weakness or tiredness
- Raised lipase or amylase on blood tests
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Dehydration
- A faster heart rate (tachycardia)
- Pancreatitis, which is inflammation of the pancreas
- Delayed stomach emptying
- Inflammation of the gall bladder (cholecystitis)
- Nettle rash (urticaria)
- Generally feeling unwell
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Anaphylactic reaction, a sudden and severe whole-body allergic reaction
- Acute kidney failure
- Kidney impairment
Frequency not known
frequency not known (cannot be estimated from the available data)
reported, but nobody can yet say how often it happens
- Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market
- Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site
Erwachsene mit Adipositas (BMI ≥30) oder Übergewicht (BMI ≥27) mit mindestens einer gewichtsbedingten Begleiterkrankung wie Typ-2-Diabetes, Bluthochdruck oder Fettstoffwechselstörung.
- Tägliche Selbstinjektion in Oberschenkel, Bauch oder Oberarm, zu jeder Tageszeit, idealerweise immer zur gleichen.
- Die Dosis wird Woche für Woche bis zur Erhaltungsdosis gesteigert, um Magen-Darm-Beschwerden zu begrenzen.
- Wirkt zusammen mit Ernährung und Bewegung – es ersetzt die Lebensstiländerung nicht.
WER ES NICHT EINNEHMEN DARF UND WER BESONDERE VORSICHT BRAUCHT
- You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
- You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
- You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
- You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
- You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
- You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
- You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
- You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
- You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
- You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.
Wann Sie dringend Hilfe suchen sollten
Bei schweren, plötzlichen oder unerwarteten Symptomen rufen Sie den örtlichen Notruf an oder suchen Sie die nächste Notaufnahme auf. Informieren Sie danach Ihren Arzt über den Chat Ihres Kontos.
Arzneimittel und Substanzen mit Wechselwirkungen
| ARZNEIMITTEL ODER SUBSTANZ | WAS PASSIEREN KANN | WAS DIE ÄRZTIN ODER DER ARZT TUT |
|---|---|---|
| Insulin and sulfonylureas (for example gliclazide) | Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. | The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring. |
| Other GLP-1 receptor agonists | Two medicines acting on the same receptor add side effects without an established extra benefit. | Liraglutide for weight management must not be combined with another GLP-1 receptor agonist. |
| Warfarin and other coumarin blood thinners | No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. | The prescriber arranges more frequent INR checks when liraglutide is started. |
| Oral medicines in general | Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. | Interaction studies showed no clinically relevant delay, so no dose change is required. |
| Paracetamol | Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. | No dose adjustment is needed for paracetamol taken alongside liraglutide. |
| Combined oral contraceptives | Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. | The contraceptive effect is expected to be unaffected, so no change is required. |
| Atorvastatin, digoxin and lisinopril | Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. | No dose adjustment of any of these three is required based on those results. |
| General anaesthesia or deep sedation | Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. | Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation. |
Ihren Fall ärztlich prüfen lassenGenau das prüft die Ärztin oder der Arzt, bevor überhaupt etwas verordnet wird.
Vollständige Sicherheitsübersicht zu Liraglutide lesenEVIDENZ
Was die klinischen Studien ergaben
The SCALE phase 3 programme tested liraglutide 3.0 mg once daily against placebo in 5,358 adults, and reported a mean body-weight change of -8.0% at 56 weeks compared with -2.6% on placebo.
3,731 adults with BMI >= 30, or >= 27 with dyslipidaemia or hypertension · 56 weeks
SCALE Obesity and Prediabetes. Placebo changed -2.6%. In kilograms the change was -8.4 kg versus -2.8 kg from a mean baseline of 106.3 kg.
Quelle: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics3,731 adults without type 2 diabetes · 56 weeks
In the same trial 26.6% of the placebo group reached 5%. For a loss of more than 10% the figures were 32.8% and 10.1%.
Quelle: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes at screening · 160 weeks
Placebo changed -1.8%. The weight loss occurred mainly in the first year and was sustained through week 160.
Quelle: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes and obesity or overweight · 160 weeks
Estimated time to onset of type 2 diabetes was 2.7 times longer on liraglutide, with a hazard ratio of 0.2 versus placebo.
Quelle: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics422 adults who had already lost at least 5% on a low-calorie diet · 56 weeks
SCALE Maintenance. Placebo changed -0.2%. 81.4% on liraglutide kept at least 5% of the run-in loss, versus 48.9% on placebo.
Quelle: SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight lossThese figures are group averages from randomised trials, not a prediction for any one person. Some participants lost far more than the average and some lost very little, and everyone in these trials was also following an energy-restricted diet with exercise counselling alongside the daily injection. The product information also notes that of the people who had lost less than 5% after 12 weeks on the full dose, 93.4% did not go on to reach a 10% loss at one year, which is why the prescriber reviews progress at that point.
ALTERNATIVEN
Liraglutide vs other EU weight-management medicines
| ARZNEIMITTEL | ANWENDUNGSFORM | WIE OFT | ÜBLICHER DOSISBEREICH | IN DER EU ZUGELASSENE INDIKATION | WICHTIGSTE EVIDENZ |
|---|---|---|---|---|---|
| Semaglutide | Wöchentliche Injektion | Einmal wöchentlich | 0.25–2.4 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | STEP 1: mean -14.9% body weight at 68 weeks versus -2.4% placebo |
| Tirzepatide | Wöchentliche Injektion | Einmal wöchentlich | 2.5–15 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | SURMOUNT-1: mean -20.9% body weight at 72 weeks versus -3.1% placebo |
| Orlistat | Kapsel zum Einnehmen | Zu jeder Hauptmahlzeit | 120 mg per main meal | In conjunction with a mildly hypocaloric diet, for obese patients with BMI ≥30, or overweight patients with BMI ≥28 and associated risk factors. | XENDOS: mean 5.8 kg lost at four years versus 3.0 kg on placebo |
Unsicher, was zu Ihnen passt? Die Ärztin oder der Arzt prüft Ihre Vorgeschichte und sagt es Ihnen.
Beratung starten · 25 €/MonatZUGANG UND KOSTEN
Liraglutide erhalten und was es kostet
Liraglutide is a centrally authorised medicine that is subject to medical prescription across the European Union, so no pharmacy can supply it without a valid prescription from a doctor. Who pays varies a lot by country: most national health systems do not cover it for weight management, so the patient pays the pharmacy directly. The entries for Spain, Germany, the Netherlands, Portugal, Ireland and Poland come from the national sources listed below; the rows for France, Italy, Belgium and Austria record the general position for this indication and are not confirmed against a national decision. The national database linked on each row is the authority on the current position.
Was Sie an Hi-Doctor zahlen
25 €/Monat (Abrechnung: 25 € alle 28 Tage)
Beantworten Sie einige Fragen und ein in der EU zugelassener Arzt prüft Ihren Fall in durchschnittlich weniger als 2 Stunden. Volle Rückerstattung, falls es nicht das Richtige für Sie ist.
Was die Apotheke berechnet
Hi-Doctor verkauft, lagert und gibt keine Arzneimittel ab und legt deren Preis nicht fest. Das Arzneimittel wird separat in der Apotheke bezahlt; der Betrag hängt vom Land, der Packungsgröße, der Verfügbarkeit eines Generikums und der Kostenübernahme ab. Die in der Tabelle verlinkte offizielle Datenbank veröffentlicht den aktuellen zugelassenen Preis.
| LAND | ABGABESTATUS | VON DER KRANKENKASSE ÜBERNOMMEN? | OFFIZIELLE QUELLE |
|---|---|---|---|
| Spanien | Verschreibungspflichtig | Not reimbursed for weight management | AEMPS CIMA |
Weitere Länder anzeigen
| Deutschland | Verschreibungspflichtig | Excluded from statutory health insurance as a weight-regulation medicine | PharmNet.Bund AMIce |
|---|---|---|---|
| Frankreich | Verschreibungspflichtig | Not reimbursed for weight management | Base de données publique des médicaments |
| Italien | Verschreibungspflichtig | Not reimbursed for weight management | AIFA Medicinali |
| Niederlande | Verschreibungspflichtig | Restricted, conditions set in Regeling zorgverzekering bijlage 2 | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Verschreibungspflichtig | Not reimbursed for weight management | INFARMED Infomed |
| Belgien | Verschreibungspflichtig | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Irland | Verschreibungspflichtig | Reimbursed by the HSE since January 2023, see national criteria | HPRA Find a Medicine |
| Österreich | Verschreibungspflichtig | Not reimbursed for weight management | BASG Medikamente Info Austria |
| Polen | Verschreibungspflichtig | Not reimbursed, patient pays in full | Rejestr Produktów Leczniczych |
PREISE
Sie zahlen nur, wenn die Behandlung genehmigt wird.
25 €/Monat für Gewichtsabnahme oder 15 €/Monat (Abrechnung: 45 € alle 90 Tage) für Haarwachstum. Für Sexualgesundheit gilt eine einmalige Konsultation zu 35 €.
Gewichtsverlust
FORTLAUFENDER PLAN
25 €/Monat
Abrechnung: 25 € alle 28 Tage · jederzeit kündbar
28-tägiger Behandlungszyklus
Für eine fortlaufende Behandlung und ärztlich geprüfte Verlängerungen.
Verlängerungen werden von Ihrem Arzt geprüft
Beratung starten
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird
WAS IST INBEGRIFFEN
- Erstberatung inklusive
- Verlängerungen werden von Ihrem Arzt geprüft
- Fortlaufende Betreuung durch Ihren Arzt
- Jederzeit kündbar
Volle Rückerstattung, wenn eine Prüfung abgelehnt wird
Wird eine Prüfung nicht genehmigt, erstatten wir die Gebühr von 25 € für diesen Zeitraum und kündigen den Plan.
Hinweis: Das Medikament, falls der Arzt es verschreibt, wird separat in der Apotheke zu dem von ihr festgelegten Preis bezahlt. Hi-Doctor verkauft keine Medikamente.
WIE DIE ÄRZTLICHE ENTSCHEIDUNG FÄLLT
Eine approbierte Ärztin oder ein Arzt prüft Ihren Fall, kein Algorithmus
Eine in der EU approbierte Ärztin oder ein Arzt liest Ihren Fragebogen und antwortet in durchschnittlich weniger als 2 Stunden.
Entscheidet die Ärztin oder der Arzt, dass eine Verordnung nicht sicher ist, wird die Gebühr vollständig erstattet.
Die Nachbetreuung läuft im privaten Chat in Ihrem Konto, DSGVO-konform. Kein WhatsApp, keine SMS.
HÄUFIG GESTELLTE FRAGEN
Fragen zu Liraglutide.
ANDERE GEWICHTSMANAGEMENT-BEHANDLUNGEN
Entdecken Sie verwandte Behandlungen.
QUELLEN
Woher diese Informationen stammen
- 01
Saxenda (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2015
- 02
Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics — European Medicines Agency, 2026
- 03
Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 04
Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet — electronic medicines compendium (emc), 2026
- 05
Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z — NHS, 2026
- 06
SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management — New England Journal of Medicine, 2015
- 07
SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss — International Journal of Obesity, 2013
- 08
Victoza (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2009
- 09
Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications — DailyMed, US National Library of Medicine, 2026
- 10
CIMA: Saxenda presentations, marketing and prescription status in Spain — AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
- 11
Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation — Bundesministerium der Justiz (gesetze-im-internet.de), 2026
- 12
Liraglutide: preparaattekst and vergoeding conditions in the Netherlands — Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
- 13
Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision — National Centre for Pharmacoeconomics (Ireland), 2023
- 14
Rejestr Produktow Leczniczych: Saxenda registration record in Poland — Centrum e-Zdrowia (Poland), 2026
- 15
INFOMED: base de dados de medicamentos de uso humano — INFARMED (Portugal), 2026
- 16
STEP 1: Once-weekly semaglutide in adults with overweight or obesity — New England Journal of Medicine, 2021
- 17
SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine, 2022
- 18
XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study — Diabetes Care, 2004
- 19
Wegovy (semaglutide) solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 20
Xenical 120 mg hard capsules: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
Geprüft vom medizinischen Team von Hi-Doctor · Zuletzt geprüft am 2026-07-27 · Nächste Prüfung fällig am 2027-07-27
Diese Seite bietet Informationen zu einem Arzneimittel. Sie ist weder eine Empfehlung zur Einnahme noch ein Ersatz für eine ärztliche Beratung. Nur eine approbierte Ärztin oder ein Arzt, die oder der Ihre Vorgeschichte geprüft hat, kann entscheiden, ob eine Behandlung für Sie geeignet ist.
Finden Sie heraus, ob es zu Ihnen passt
Prüfen Sie, ob Liraglutide für Sie geeignet ist.
Beantworten Sie einige Fragen und ein in der EU zugelassener Arzt prüft Ihren Fall in durchschnittlich weniger als 2 Stunden. Volle Rückerstattung, falls es nicht das Richtige für Sie ist.